The world's first wiki where authorship really matters (Nature Genetics, 2008). Due credit and reputation for authors. Imagine a global collaborative knowledge base for original thoughts. Search thousands of articles and collaborate with scientists around the globe.

wikigene or wiki gene protein drug chemical gene disease author authorship tracking collaborative publishing evolutionary knowledge reputation system wiki2.0 global collaboration genes proteins drugs chemicals diseases compound
Hoffmann, R. A wiki for the life sciences where authorship matters. Nature Genetics (2008)
Chemical Compound Review

Temodal     3-methyl-2-oxo-1,3,4,5,8...

Synonyms: Temodar, Temozolamide, Temozolodida, temozolomida, temozolomide, ...
 Chinot,  Honore,  Figarella-Branger,  Dufour,  Martin,  Braguer,  Barrie,  Muracciole,  Grisoli,  Danson,  Ashcroft,  Ranson,  Thatcher,  Hodgetts,  Lomax,  Clamp,  Arance,  Lorigan,  Middleton,  Tentori,  Leonetti,  Graziani,  Scarsella,  Zupi,  d'Amati,  Bonmassar,  Portarena,  Nicholson,  Ames,  Vezina,  Krailo,  Reid,  Seibel,  Ettinger,  Reaman,  Liu-Mares,  Brandes,  Tosoni,  Monfardini,  Cavallo,  Reni,  Basso,  Vastola,  Ferreri,  Scopece,  Panucci,  Ermani,  Middleton,  Grob,  Coates,  Schadendorf,  Dreno,  Aamdal,  Seiter,  Statkevich,  Henz,  Fraass,  Kapp,  Cebon,  Thatcher,  Tilgen,  Fierlbeck,  Muller,  Gore,  Aaronson,  Weiss,  Hwu,  Livingston,  Williams,  Menell,  Foster,  Chapman,  Lamb,  Wolchok,  Quinn,  Merrell,  Krown,  Panageas,  Houghton,  Johns,  Walker,  Weinstock,  Stockert,  Nice,  Burgess,  Vitali,  Jungbluth,  Murone,  Perera,  Old,  Scott,  Luwor, Bakhtiar Yamini, Xiaohong Yu, Michael H. Wu, Donald W. Kufe, Thomas E. Darga, M. Eileen Dolan, Ralph R. Weichselbaum, Bakhtiar Yamini, Vinay Rawlani, Ralph R. Weichselbaum, Kai Bickenbach, Xiaohong Yu, Peter Pytel, Nicholas Galanopoulos, Jula Veerapong,  Natsume,  Hatano,  Ishii,  Tsuno,  Wakabayashi,  Yoshida,  Mizuno, Christina K. Augustine, Yasunori Yoshimoto, Henry S. Friedman, Douglas S. Tyler, Jin Soo Yoo, Francis Ali-Osman, Joseph R. Nevins, Patricia A. Zipfel, Anil Potti,  Antonadou,  Throuvalas,  Coliarakis,  Paraskevaidis,  Economou,  Karageorgis,  Sarris,  Hillner,  Middleton,  Agarwala,  Middlemas,  Stewart,  Kirstein,  Houghton,  Poquette,  Friedman,  Brent,  
Welcome! If you are familiar with the subject of this article, you can contribute to this open access knowledge base by deleting incorrect information, restructuring or completely rewriting any text. Read more.

Disease relevance of Temodal


High impact information on Temodal


Chemical compound and disease context of Temodal


Biological context of Temodal


Anatomical context of Temodal


Associations of Temodal with other chemical compounds


Gene context of Temodal


Analytical, diagnostic and therapeutic context of Temodal


  1. Treatment of brain metastases of malignant melanoma with temozolomide. Biasco, G., Pantaleo, M.A., Casadei, S. N. Engl. J. Med. (2001) [Pubmed]
  2. Salvage therapy with temozolomide in an immunocompetent patient with primary brain lymphoma. Reni, M., Ferreri, A.J., Landoni, C., Villa, E. J. Natl. Cancer Inst. (2000) [Pubmed]
  3. Antitumor efficacy of cytotoxic drugs and the monoclonal antibody 806 is enhanced by the EGF receptor inhibitor AG1478. Johns, T.G., Luwor, R.B., Murone, C., Walker, F., Weinstock, J., Vitali, A.A., Perera, R.M., Jungbluth, A.A., Stockert, E., Old, L.J., Nice, E.C., Burgess, A.W., Scott, A.M. Proc. Natl. Acad. Sci. U.S.A. (2003) [Pubmed]
  4. O6-benzylguanine potentiates the in vivo toxicity and clastogenicity of temozolomide and BCNU in mouse bone marrow. Chinnasamy, N., Rafferty, J.A., Hickson, I., Ashby, J., Tinwell, H., Margison, G.P., Dexter, T.M., Fairbairn, L.J. Blood (1997) [Pubmed]
  5. Combined treatment with temozolomide and poly(ADP-ribose) polymerase inhibitor enhances survival of mice bearing hematologic malignancy at the central nervous system site. Tentori, L., Leonetti, C., Scarsella, M., d'Amati, G., Portarena, I., Zupi, G., Bonmassar, E., Graziani, G. Blood (2002) [Pubmed]
  6. Adenovirally delivered tumor necrosis factor-alpha improves the antiglioma efficacy of concomitant radiation and temozolomide therapy. Yamini, B., Yu, X., Pytel, P., Galanopoulos, N., Rawlani, V., Veerapong, J., Bickenbach, K., Weichselbaum, R.R. Clin. Cancer Res. (2007) [Pubmed]
  7. Manipulation of base excision repair to sensitize ovarian cancer cells to alkylating agent temozolomide. Fishel, M.L., He, Y., Smith, M.L., Kelley, M.R. Clin. Cancer Res. (2007) [Pubmed]
  8. Predicting human tumor drug concentrations from a preclinical pharmacokinetic model of temozolomide brain disposition. Zhou, Q., Guo, P., Kruh, G.D., Vicini, P., Wang, X., Gallo, J.M. Clin. Cancer Res. (2007) [Pubmed]
  9. Mismatch repair deficiency does not mediate clinical resistance to temozolomide in malignant glioma. Maxwell, J.A., Johnson, S.P., McLendon, R.E., Lister, D.W., Horne, K.S., Rasheed, A., Quinn, J.A., Ali-Osman, F., Friedman, A.H., Modrich, P.L., Bigner, D.D., Friedman, H.S. Clin. Cancer Res. (2008) [Pubmed]
  10. Genomic and molecular profiling predicts response to temozolomide in melanoma. Augustine, C.K., Yoo, J.S., Potti, A., Yoshimoto, Y., Zipfel, P.A., Friedman, H.S., Nevins, J.R., Ali-Osman, F., Tyler, D.S. Clin. Cancer Res. (2009) [Pubmed]
  11. Phase II Trial of Temozolomide in Patients with Relapsed Sensitive or Refractory Small Cell Lung Cancer, with Assessment of Methylguanine-DNA Methyltransferase as a Potential Biomarker. Pietanza, M.C., Kadota, K., Huberman, K., Sima, C.S., Fiore, J.J., Sumner, D.K., Travis, W.D., Heguy, A., Ginsberg, M.S., Holodny, A.I., Chan, T.A., Rizvi, N.A., Azzoli, C.G., Riely, G.J., Kris, M.G., Krug, L.M. Clin. Cancer Res. (2012) [Pubmed]
  12. Systemic therapy of cutaneous T-cell lymphomas (mycosis fungoides and the Sézary syndrome). Bunn, P.A., Hoffman, S.J., Norris, D., Golitz, L.E., Aeling, J.L. Ann. Intern. Med. (1994) [Pubmed]
  13. Tolerance of human MSH2+/- lymphoblastoid cells to the methylating agent temozolomide. Marra, G., D'Atri, S., Corti, C., Bonmassar, L., Cattaruzza, M.S., Schweizer, P., Heinimann, K., Bartosova, Z., Nyström-Lahti, M., Jiricny, J. Proc. Natl. Acad. Sci. U.S.A. (2001) [Pubmed]
  14. Msh2 status modulates both apoptosis and mutation frequency in the murine small intestine. Toft, N.J., Winton, D.J., Kelly, J., Howard, L.A., Dekker, M., te Riele, H., Arends, M.J., Wyllie, A.H., Margison, G.P., Clarke, A.R. Proc. Natl. Acad. Sci. U.S.A. (1999) [Pubmed]
  15. Mutagenic potential of temozolomide in bone marrow cells in vivo. Geiger, H., Schleimer, D., Nattamai, K.J., Dannenmann, S.R., Davies, S.M., Weiss, B.D. Blood (2006) [Pubmed]
  16. Polyclonal chemoprotection against temozolomide in a large-animal model of drug resistance gene therapy. Neff, T., Beard, B.C., Peterson, L.J., Anandakumar, P., Thompson, J., Kiem, H.P. Blood (2005) [Pubmed]
  17. Preclinical antitumor activity of temozolomide in mice: efficacy against human brain tumor xenografts and synergism with 1,3-bis(2-chloroethyl)-1-nitrosourea. Plowman, J., Waud, W.R., Koutsoukos, A.D., Rubinstein, L.V., Moore, T.D., Grever, M.R. Cancer Res. (1994) [Pubmed]
  18. Role of autophagy in temozolomide-induced cytotoxicity for malignant glioma cells. Kanzawa, T., Germano, I.M., Komata, T., Ito, H., Kondo, Y., Kondo, S. Cell Death Differ. (2004) [Pubmed]
  19. First-line chemotherapy with cisplatin plus fractionated temozolomide in recurrent glioblastoma multiforme: a phase II study of the Gruppo Italiano Cooperativo di Neuro-Oncologia. Brandes, A.A., Basso, U., Reni, M., Vastola, F., Tosoni, A., Cavallo, G., Scopece, L., Ferreri, A.J., Panucci, M.G., Monfardini, S., Ermani, M. J. Clin. Oncol. (2004) [Pubmed]
  20. Phase II study of temozolomide plus thalidomide for the treatment of metastatic melanoma. Hwu, W.J., Krown, S.E., Menell, J.H., Panageas, K.S., Merrell, J., Lamb, L.A., Williams, L.J., Quinn, C.J., Foster, T., Chapman, P.B., Livingston, P.O., Wolchok, J.D., Houghton, A.N. J. Clin. Oncol. (2003) [Pubmed]
  21. Post hoc economic analysis of temozolomide versus dacarbazine in the treatment of advanced metastatic melanoma. Hillner, B.E., Agarwala, S., Middleton, M.R. J. Clin. Oncol. (2000) [Pubmed]
  22. The addition of bevacizumab to standard radiation therapy and temozolomide followed by bevacizumab, temozolomide, and irinotecan for newly diagnosed glioblastoma. Vredenburgh, J.J., Desjardins, A., Reardon, D.A., Peters, K.B., Herndon, J.E., Marcello, J., Kirkpatrick, J.P., Sampson, J.H., Bailey, L., Threatt, S., Friedman, A.H., Bigner, D.D., Friedman, H.S. Clin. Cancer Res. (2011) [Pubmed]
  23. The role of base excision repair in the sensitivity and resistance to temozolomide-mediated cell death. Trivedi, R.N., Almeida, K.H., Fornsaglio, J.L., Schamus, S., Sobol, R.W. Cancer Res. (2005) [Pubmed]
  24. Phase I trial of temozolomide using an extended continuous oral schedule. Brock, C.S., Newlands, E.S., Wedge, S.R., Bower, M., Evans, H., Colquhoun, I., Roddie, M., Glaser, M., Brampton, M.H., Rustin, G.J. Cancer Res. (1998) [Pubmed]
  25. Phase I study of temozolomide in children and adolescents with recurrent solid tumors: a report from the Children's Cancer Group. Nicholson, H.S., Krailo, M., Ames, M.M., Seibel, N.L., Reid, J.M., Liu-Mares, W., Vezina, L.G., Ettinger, A.G., Reaman, G.H. J. Clin. Oncol. (1998) [Pubmed]
  26. MGMT methylation: A marker of response to temozolomide in low-grade gliomas. Everhard, S., Kaloshi, G., Crini??re, E., Benouaich-Amiel, A., Lejeune, J., Marie, Y., Sanson, M., Kujas, M., Mokhtari, K., Hoang-Xuan, K., Delattre, J.Y., Thillet, J. Ann. Neurol. (2006) [Pubmed]
  27. In vitro and in vivo methazolastone-induced DNA damage and repair in L-1210 leukemia sensitive and resistant to chloroethylnitrosoureas. Catapano, C.V., Broggini, M., Erba, E., Ponti, M., Mariani, L., Citti, L., D'Incalci, M. Cancer Res. (1987) [Pubmed]
  28. Activity of temozolomide in the treatment of central nervous system tumor xenografts. Friedman, H.S., Dolan, M.E., Pegg, A.E., Marcelli, S., Keir, S., Catino, J.J., Bigner, D.D., Schold, S.C. Cancer Res. (1995) [Pubmed]
  29. Temozolomide in combination with docetaxel in patients with advanced melanoma: a phase II study of the Hellenic Cooperative Oncology Group. Bafaloukos, D., Gogas, H., Georgoulias, V., Briassoulis, E., Fountzilas, G., Samantas, E., Kalofonos, C.h., Skarlos, D., Karabelis, A., Kosmidis, P. J. Clin. Oncol. (2002) [Pubmed]
  30. Combined effects of adenovirus-mediated wild-type p53 transduction, temozolomide and poly (ADP-ribose) polymerase inhibitor in mismatch repair deficient and non-proliferating tumor cells. Tentori, L., Portarena, I., Bonmassar, E., Graziani, G. Cell Death Differ. (2001) [Pubmed]
  31. Human Monocytes, but not Dendritic Cells Derived from Them, Are Defective in Base Excision Repair and Hypersensitive to Methylating Agents. Briegert, M., Kaina, B. Cancer Res. (2007) [Pubmed]
  32. Distinct responses of xenografted gliomas to different alkylating agents are related to histology and genetic alterations. Leuraud, P., Taillandier, L., Medioni, J., Aguirre-Cruz, L., Crinière, E., Marie, Y., Kujas, M., Golmard, J.L., Duprez, A., Delattre, J.Y., Sanson, M., Poupon, M.F. Cancer Res. (2004) [Pubmed]
  33. Randomized phase II study of temozolomide given every 8 hours or daily with either interferon alfa-2b or thalidomide in metastatic malignant melanoma. Danson, S., Lorigan, P., Arance, A., Clamp, A., Ranson, M., Hodgetts, J., Lomax, L., Ashcroft, L., Thatcher, N., Middleton, M.R. J. Clin. Oncol. (2003) [Pubmed]
  34. Randomized phase III study of temozolomide versus dacarbazine in the treatment of patients with advanced metastatic malignant melanoma. Middleton, M.R., Grob, J.J., Aaronson, N., Fierlbeck, G., Tilgen, W., Seiter, S., Gore, M., Aamdal, S., Cebon, J., Coates, A., Dreno, B., Henz, M., Schadendorf, D., Kapp, A., Weiss, J., Fraass, U., Statkevich, P., Muller, M., Thatcher, N. J. Clin. Oncol. (2000) [Pubmed]
  35. Phase II study of temozolomide, thalidomide, and celecoxib for newly diagnosed glioblastoma in adults. Kesari, S., Schiff, D., Henson, J.W., Muzikansky, A., Gigas, D.C., Doherty, L., Batchelor, T.T., Longtine, J.A., Ligon, K.L., Weaver, S., Laforme, A., Ramakrishna, N., Black, P.M., Drappatz, J., Ciampa, A., Folkman, J., Kieran, M., Wen, P.Y. Neuro-oncology (2008) [Pubmed]
  36. IFN-beta down-regulates the expression of DNA repair gene MGMT and sensitizes resistant glioma cells to temozolomide. Natsume, A., Ishii, D., Wakabayashi, T., Tsuno, T., Hatano, H., Mizuno, M., Yoshida, J. Cancer Res. (2005) [Pubmed]
  37. Human melanoma cells expressing V600E B-RAF are susceptible to IGF1R targeting by small interfering RNAs. Yeh, A.H., Bohula, E.A., Macaulay, V.M. Oncogene (2006) [Pubmed]
  38. Biochemical correlates of temozolomide sensitivity in pediatric solid tumor xenograft models. Middlemas, D.S., Stewart, C.F., Kirstein, M.N., Poquette, C., Friedman, H.S., Houghton, P.J., Brent, T.P. Clin. Cancer Res. (2000) [Pubmed]
  39. DNA damage induced by temozolomide signals to both ATM and ATR: role of the mismatch repair system. Caporali, S., Falcinelli, S., Starace, G., Russo, M.T., Bonmassar, E., Jiricny, J., D'Atri, S. Mol. Pharmacol. (2004) [Pubmed]
  40. Inhibition of nuclear factor-kappaB activity by temozolomide involves O6-methylguanine induced inhibition of p65 DNA binding. Yamini, B., Yu, X., Dolan, M.E., Wu, M.H., Darga, T.E., Kufe, D.W., Weichselbaum, R.R. Cancer Res. (2007) [Pubmed]
  41. Repopulating defect of mismatch repair-deficient hematopoietic stem cells. Reese, J.S., Liu, L., Gerson, S.L. Blood (2003) [Pubmed]
  42. Safety and efficacy of temozolomide in patients with recurrent anaplastic oligodendrogliomas after standard radiotherapy and chemotherapy. Chinot, O.L., Honore, S., Dufour, H., Barrie, M., Figarella-Branger, D., Muracciole, X., Braguer, D., Martin, P.M., Grisoli, F. J. Clin. Oncol. (2001) [Pubmed]
  43. Phase II randomized trial of temozolomide and concurrent radiotherapy in patients with brain metastases. Antonadou, D., Paraskevaidis, M., Sarris, G., Coliarakis, N., Economou, I., Karageorgis, P., Throuvalas, N. J. Clin. Oncol. (2002) [Pubmed]
WikiGenes - Universities